Article Text

This article has a correction. Please see:

Download PDFPDF
Valvular heart disease: the next cardiac epidemic
  1. J L d'Arcy1,
  2. B D Prendergast1,
  3. J B Chambers2,
  4. S G Ray3,4,
  5. B Bridgewater3,4,5
  1. 1John Radcliffe Hospital, Oxford, UK
  2. 2St Thomas' Hospital, London, UK
  3. 3University Hospital of South Manchester, Manchester, UK
  4. 4Manchester Academic Health Sciences Centre, Manchester, UK
  5. 5National Institute for Clinical Outcomes Research, Manchester, UK
  1. Correspondence to Mr Ben Bridgewater, Department of Cardiothoracic Surgery, South Manchester University Hospital, Southmoor Road, Manchester M23 9LT, UK; ben.bridgewater{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The increasing burden of valvular heart disease

The epidemiology of valvular heart disease (VHD) has changed dramatically over the past 50 years in developed nations. While rheumatic disease is now uncommon, a steady rise in life expectancy has been accompanied by a progressively increasing frequency of degenerative valve disease. Although an accurate overall picture of the epidemiology of VHD has yet to be established, the overall prevalence in the USA is 2.5% with wide age-related variation from 0.7% in those aged 18–44 years to 13.3% in those over the age of 75.1 Similar age dependency has been shown in hospital-based surveys in Europe.2 3 Population statistics worldwide project an imminent increase in the elderly population—in the UK, for example, there will be an estimated 4 million people aged between 75 and 84 in the UK by 2018, and the population beyond the age of 85 is set to double by 2028. VHD is associated with significant morbidity and mortality,2 and treatment, particularly by valve surgery, is expensive. Furthermore, research concerning the epidemiology, pathophysiology and clinical management of VHD is limited. Mechanisms underlying aortic stenosis are poorly elucidated and those involved in mitral regurgitation are virtually unknown.

Accurate data concerning the contemporary prevalence and natural history of VHD are required to inform economists and policy makers responsible for healthcare planning and the allocation of resources to newer developments, such as percutaneous valve implantation and repair. The recent National Adult Cardiac Surgery Database report for Great Britain and Ireland provides important detail not available in more general surveys—including a significant increase in all types of valve surgery and variation in the type of surgery over time and between hospitals—and highlights limitations and geographical variation in the current provision of healthcare for VHD.4

The care pathway for VHD

VHD may be detected as an incidental finding in the asymptomatic patient or manifest at …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • PostScript
    BMJ Publishing Group Ltd and British Cardiovascular Society